Austedo (deutetrabenazine) / Teva  >>  Phase 3
Welcome,         Profile    Billing    Logout  

11 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Austedo (deutetrabenazine) / Teva
First-HD, NCT01795859: First Time Use of SD-809 in Huntington Disease

Completed
3
90
US, Canada, RoW
SD-809, deutetrabenazine, Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Chorea
12/14
12/14
AIM-TD, NCT02291861 / 2014-003135-19: Addressing Involuntary Movements in Tardive Dyskinesia

Completed
3
298
Europe, US, RoW
SD-809, deutetrabenzine, Austedo, Placebo
Auspex Pharmaceuticals, Inc.
Tardive Dyskinesia
08/16
08/16
NCT01897896: Alternatives for Reducing Chorea in Huntington Disease

Completed
3
119
Canada, US, RoW
SD-809, Deutetrabenazine
Auspex Pharmaceuticals, Inc.
Chorea Associated With Huntington Disease
08/17
08/17
RIM-TD, NCT02198794 / 2014-001891-73: Reducing Involuntary Movements in Participants With Tardive Dyskinesia

Completed
3
343
Europe, US, RoW
SD-809, Deutetrabenazine; TEV-50717, Placebo
Auspex Pharmaceuticals, Inc.
Tardive Dyskinesia
12/19
12/20
ARTISTS 2, NCT03571256 / 2017-002976-24: A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

Checkmark Efficacy data from ARTISTS2 study in moderate to severe Tourette Syndrome
Feb 2020 - Feb 2020: Efficacy data from ARTISTS2 study in moderate to severe Tourette Syndrome
Completed
3
158
Europe, US, RoW
TEV-50717, AUSTEDO, Deutetrabenazine, Placebo
Teva Branded Pharmaceutical Products R&D, Inc., Nuvelution TS Pharma, Inc.
Tourette Syndrome
12/19
12/19
ARTISTS, NCT03567291 / 2016-000630-22: Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Terminated
3
228
Europe, Canada, US, RoW
TEV-50717, deutetrabenazine, SD-809, Placebo
Teva Branded Pharmaceutical Products R&D, Inc., Nuvelution TS Pharma, Inc.
Tourette Syndrome
05/20
05/20
NCT03813238 / 2018-003742-17: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

Completed
3
63
Europe, Canada, US, RoW
TEV-50717, Deutetrabenazine, (previously SD-809), Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Cerebral Palsy, Dyskinetic
07/22
07/22
NCT04200352 / 2019-001807-19: A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

Terminated
3
44
Europe, US, RoW
TEV-50717, Deutetrabenazine, SD-809
Teva Branded Pharmaceutical Products R&D, Inc.
Cerebral Palsy, Dyskinetic
02/23
02/23
ARM-TD, NCT02195700 / 2014-001890-15: Aim to Reduce Movements in Tardive Dyskinesia

Completed
2/3
117
Europe, US, RoW
SD-809, deutetrabenazine, AUSTEDO®, Placebo
Auspex Pharmaceuticals, Inc.
Tardive Dyskinesia
05/15
05/15
ARTISTS1, NCT03452943 / 2016-000622-19: Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

Checkmark Efficacy data from ARTISTS1 study in moderate to severe Tourette Syndrome
Feb 2020 - Feb 2020: Efficacy data from ARTISTS1 study in moderate to severe Tourette Syndrome
Completed
2/3
119
Europe, Canada, US, RoW
TEV-50717, Deutetrabenazine, Placebo
Teva Branded Pharmaceutical Products R&D, Inc., Nuvelution TS Pharma, Inc.
Tourette Syndrome
11/19
11/19
NCT04713982: Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Recruiting
2/3
30
US
Deutetrabenazine, Austedo
Vanderbilt University Medical Center, Teva Branded Pharmaceutical Products R&D, Inc.
Huntington Disease
08/24
04/25

Download Options